☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
BeiGene
BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous...
July 21, 2023
BeiGene Reports the US FDA Acceptance of sNDA for Brukinsa + Obinutuzumab for Adult Patients with R/R Follicular Lymphoma
July 13, 2023
BeiGene Collaborated with DualityBio to Advance Differentiated Antibody Drug Conjugate Therapy for Solid Tumors
July 10, 2023
BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia
January 20, 2023
BeiGene Reports the NMPA’s Acceptance of sBLA for Tislelizumab for 1L Treatment of Hepatocellular Carcinoma
January 2, 2023
Insights+: EMA Marketing Authorization of New Drugs in November 2022
December 28, 2022
Load more...
Back to Home